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Surgical resection is the only treatment with the potential for cure
in hepatocellular carcinoma (HCC). In the case of unresectable
tumour, regional intra-arterial treatment has become the treatment
of choice, leading to response rates of 55 to 90% (Onohara et al,
1988; Sasaki et al, 1997; Fujimoto et al, 1985; Konno et al, 1983;
Beppu et al, 1991). However, for patients with extrahepatic
disease, systemic treatment might be the only therapeutical
option. 
Among systemic treatment modalities for advanced HCC,
doxorubicin has been one of the most widely used and most active
agents (Falkson et al, 1978, 1984; Lai et al, 1988). However,
considering both, the modest response rates of less than 20% and
the pronounced treatment related toxicities, doxorubicin is not
considered a major breakthrough in the treatment of HCC
(Mathurin et al, 1998). 
In contrast to free doxorubicin, pegylated liposomal doxoru-
bicin (PLD) – a stealth liposome formula of doxorubicin – ensures
longer circulation time and preferential accumulation in tumour
tissue, thus resulting in both, higher therapeutic efficacy and
reduced toxicity (Gabizon et al, 1986; Gabizon and Martin, 1997).
Whereas PLD appears to be superior to doxorubicin in the murine
model (Zou et al, 1993), little is known on the therapeutic efficacy
and safety of PLD in the treatment of HCC, particularly when
administered intravenously (i.v.). 
The aim of this pilot study was to test the efficacy and toxicity
of i.v. PLD in patients with advanced HCC. Since with the
standard FDA-approved protocol of 50 mg/m2 (Muggia et al,
1997; Ranson et al, 1997) significant skin toxicities and
mucositis have been reported, our protocol was to administer
40 mg/m2 only. 
PATIENTS AND METHODS 
Patients 
Seventeen patients (10 male, 7 female) with metastatic or unre-
sectable HCC entered the study. The patients characteristics
are given in Table 1. No patient had previously received adjuvant
or palliative chemotherapy. Eligibility criteria consisted of an
expected survival of at least 3 months, age between 19 and 80
years, a Karnofsky performance status of at least 80%, adequate
bone marrow function with white blood cell count above
3000/µ l, platelet count above 75 000/µ l, haemoglobin above
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Table 1 Patient characteristics 
Characteristic n = Number of patients 
Entered 17 
Evaluable toxicity 17 
Evaluable response 14 
Age, years 
Median 63 
Range 29–76 
Sex 
Male 10 
Female 7 
Liver cirrhosis 13 
Child A/B 10/3 
Chronic hepatitis B/C 3/5 
Treatment prior to disease progression 
Liver transplantation 3 
Resection 3 
Cryotherapy 3 
Interferon-alpha 5 
Tumour Stage (UICC 1997) 
III B 3 
IV A 7 
IV B 6 
Extrahepatic Disease 6 
Visceral 1 
Non-visceral 5 Liposomal doxorubicin and hepatocellular carcinoma 1851
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10 mg% and organ functions within normal ranges. All patients had
to give informed consent according to institutionals regulations.
Three patients became ineligible for response analysis. One
patient died before the first tumour-reassessment from a therapy-
unrelated endocarditis. Two patients were withdrawn from the
study due to the misinterpretation of an incompatibility reaction
after an undue preparation of the infusion. Finally, there were 14
patients eligible for the analysis of efficacy whereas all patients
were eligible for final toxicity evaluation. 
Treatment plan and patient evaluation 
PLD (Caelyx, licensed by Aesca Ges.m.b.H. Badener Straße 23,
A-2514 Traiskirchen, Austria) was diluted in 500 ml glucose 5%
and administered intravenously every 28 days at a dose of
40 mg/m2. The prophylactic anti-emetic treatment consisted of
8 mg ondansetron and 4 mg dexamethasone given intravenously.
A minimum of three courses of treatment had to be given before
the first tumour reassessment. In case of remission or stabiliza-
tion of disease, additional treatment courses were administered
until disease progression. 
In case of WHO grade III toxicity, the dose of PLD was reduced
by 25%. Any WHO grade 4 toxicity led to discontinuation of
therapy and withdrawal of the patient from treatment. 
Statistical analysis 
Survival curves were calculated and plotted according to the
method of Kaplan and Meier. Statistical comparisons of survival
were done using Wilcoxon’s test. P values below 0.05 were
considered significant. 
RESULTS 
Toxicity 
A total of 81 courses (median 3 per patient, range 1–24) were
given to the patients. WHO grade III myelotoxicities included
leucopenia, anaemia and thrombopenia in 12%, 6% and 6% of the
patients, respectively. No cardiotoxicity was observed as assessed
by physical symptoms and electrocardiography. No patient suf-
fered from nausea or vomiting. Two patients experienced bron-
chospasm immediately after initiation of PLD-infusion. These
events were first misinterpreted as a hypersensitivity reaction. In
retrospect, this reaction was felt to be an incompatibility reaction
to an undue preparation of the infusion. The line was not as
required by the manufacture filled with glucose 5% but filled with
normal saline. As a result of this misinterpretation these two
patients were withdrawn from the drug regimen. 
Response 
Response was assessed by computed tomography or magnetic
resonance imaging. Objective tumour remissions were observed in
2 out of 14 patients (14%) (CR n = 1 (7%), MR n = 1 (7%) with a
response duration of 24+ months both. The CR was verified by
liver biopsy. Five patients (36%) experienced stable disease (SD)
with a median duration of 6 months (range 3–11 months). Seven
(50%) patients progressed under this treatment. 
Alpha-fetoprotein (AFP) serum levels in the patient achieving
CR decreased during the treatment from 76572 kU/L to a normal
range (i.e. below 7 kU/L). In the patients with SD, AFP decreased
from 38585 kU/l to 3027 kU/L (n = 1), remained within the
normal range (n = 1), or increased (n = 3) from a median of 332
(range; 14–384) up to 1101 (range; 42–2160) kU/L, respectively. 
Survival 
At the time of analysis, the median time of follow-up is 27 months
(range 10–44 months). The overall survival of all 17 patients was
median 12 months (range 1–27 + months). The survival of patients
with clinical benefit response (CR, MR or SD) and PD was 13 and
6 months, respectively. The two patients achieving objective
remissions (CR and MR) are alive both 27 months after diagnosis
of advanced disease without any signs of disease progression. 
DISCUSSION 
The major finding of this study is that i.v. PLD is effective in terms
of long-lasting objective remissions (OR) (14%) and long-lasting
disease stabilizations (36%) in some patients with advanced HCC.
At the time of analysis, the two patients achieving OR were alive
27 months since diagnosis of unresectable HCC. For the patient
with CR, a liver transplantation is scheduled now. 
To the best of our knowledge, only two authors have reported on
their experience with i.v. PLD for HCC, with one case report
showing encouraging results (Hong et al, 2000) and one phase II
study showing neither OR nor SD (Halm et al, 2000). 
Since our patient population appears comparable to those of the
Halm-study in terms of age, WHO performance status and tumour
stage, the different outcome (clinical benefit response 50% in our
study versus neither OR nor SD in the Halm trial) might be
explained by the dose-regimen. In our study all patients received
40 mg/m2 PLD, whereas the dose in the Halm-trial was in the
majority (75%) of the cycles 30 mg/m2 only. 
In our study, patients with SD showed only a trend toward a
prolonged survival when compared to patients with PD. However,
these data should be interpreted cautiously. First, the size of our
study is too small to detect any statistical significant survival
difference between these sub-groups. Second, as recently shown,
the median survival of patients with HCC varies from 2.6 to 15.2
months dependent upon several prognostic features, such as portal
vein thrombosis, tumour-mass, AFP-value and so on (Schoniger-
Hekele et al, 2001). Therefore, one could argue that our patients
might belong to a prognostic favourable sub-group. Third, from
our small trial it remains unclear as to whether the survival length
of our patients achieving SD is due to the specific antitumour
treatment or might have been achieved with best supportive care
alone. Whereas the superiority of a specific antitumour treatment
over best supportive care has been demonstrated for other highly
aggressive tumours (Ahlgren, 1996; Scheithauer et al, 1999;
Hoffman and Glimelius, 1998; Burris et al, 1997), meta-analyses
from randomized trials using doxorubicin for HCC did not reveal
any survival benefit (Mathurin et al, 1998; Simonetti et al, 1997).
However, these data were generated from the treatment with the
free drug doxorubicin. The liposomal form, which was used in the
present trial, might have higher therapeutic efficacy even in a
highly chemoresistant tumour such as HCC. 
A further observation of this pilot-study was the favourable
toxicity-profile of PLD. Myelotoxicity was generally moderate.1852 M Schmidinger et al
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Similar favourable results were reported from studies using 45–50
mg/m2 PLD in patients with advanced sarcoma (Judson et al,
2001), malignant mesothelioma (Baas et al, 2000), ovarian cancer
(Gordon et al, 2000) and breast cancer. Higher myelotoxicities
occurred only at dose levels beyond 60 mg/m2 (Ranson et al, 1997).
In contrast to the moderate myelotoxicity, palmar-plantar
erythrodysesthesia (PPE) was reported to be a major adverse event
in these studies (Judson et al, 2001; Baas et al, 2000; Muggia et al,
1997). In accordance with the findings of Ranson et al, who found
PPE to be greatly reduced at a dose of 45 mg/m2 PLD, the lack of
PPE in our trial might be explained by the dose of 40 mg/m2. 
As no patient suffered from nausea and vomiting in our own study
and those from other investigators, PLD seems not to be particularly
emetogenic. This is even true for PLD-trials performed without
prophylactic anti-emetics (Halm et al, 2000; Toma et al, 2000). The
reason for including a prophylactic anti-emetic treatment in our
protocol was the lack of personal experience and of sufficient clin-
ical data on PLD at the time when our trial was initiated. In view of
our own results and the findings of other investigators, we now
strongly support that PLD, when given as monotherapy, does not
require the routine co-administration of anti-emetics. 
Finally, since none – and this is true even for the patient
receiving 24 courses of PLD – did experience any cardiotoxicity,
PLD can be considered safe and feasible in an outpatient-setting. 
We conclude that i.v. PLD can result in objective tumour remis-
sions and long-lasting disease stabilization in patients with metastatic
or unresectable HCC. Due to the lack of appropriate sized studies, the
role of PLD in advanced HCC is not definitely defined yet. 
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